Get the Stockscreener App
22.10
6.09%
1.36
Dianthus Therapeutics Inc stock is traded at $22.10, with a volume of 97,023.
It is up +6.09% in the last 24 hours and up +27.92% over the past month.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
See More
Previous Close:
$20.74
Open:
$21.05
24h Volume:
97,023
Relative Volume:
0.33
Market Cap:
$710.74M
Revenue:
$4.12M
Net Income/Loss:
$-56.68M
P/E Ratio:
-3.9871
EPS:
-5.5429
Net Cash Flow:
$-51.44M
1W Performance:
+10.90%
1M Performance:
+27.92%
6M Performance:
-1.25%
1Y Performance:
-21.36%
1-Day Range:
$20.71
$22.49
1-Week Range:
$19.73
$22.49
52-Week Range:
$13.37
$32.27
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Name
Dianthus Therapeutics Inc
Sector
Industry
Phone
929-999-4055
Address
7 TIMES SQUARE, NEW YORK
Compare DNTH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
22.10 | 612.33M | 4.12M | -56.68M | -51.44M | -5.5429 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.55 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.20 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.06 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
573.11 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.85 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-02-25 | Initiated | William Blair | Outperform |
| Dec-20-24 | Initiated | TD Cowen | Buy |
| Oct-03-24 | Initiated | Oppenheimer | Outperform |
| Jul-26-24 | Initiated | Robert W. Baird | Outperform |
| Jun-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-24 | Initiated | H.C. Wainwright | Buy |
| Feb-15-24 | Initiated | Stifel | Buy |
| Dec-26-23 | Initiated | Jefferies | Buy |
| Nov-22-23 | Initiated | Wedbush | Outperform |
| Oct-30-23 | Initiated | Guggenheim | Buy |
| Sep-28-23 | Initiated | Raymond James | Outperform |
| Aug-25-22 | Downgrade | Goldman | Buy → Neutral |
| Jan-06-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-20-21 | Resumed | Goldman | Neutral |
| Aug-03-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-22-21 | Reiterated | B. Riley Securities | Buy |
| Jun-29-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-18-21 | Initiated | B. Riley Securities | Buy |
| Jan-07-21 | Initiated | Mizuho | Buy |
| Jun-08-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-25-19 | Downgrade | Goldman | Buy → Neutral |
| Mar-15-19 | Initiated | Raymond James | Outperform |
View All
Dianthus Therapeutics Inc Stock (DNTH) Latest News
What drives Dianthus Therapeutics Inc. stock priceHigh-profit trading signals - jammulinksnews.com
Dianthus Therapeutics Inc. Stock Analysis and ForecastSuperior portfolio returns - jammulinksnews.com
What analysts say about Dianthus Therapeutics Inc. stockGame-changing returns - jammulinksnews.com
Is Dianthus Therapeutics Inc. a good long term investmentRapid wealth creation - jammulinksnews.com
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Up 5.9%Should You Buy? - MarketBeat
Brokerages Set Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Target Price at $53.00 - MarketBeat
why dianthus therapeutics inc. stock attracts strong analyst attentionSafe and Smart Investment Picks - Newser
what makes dianthus therapeutics inc. stock price move sharplyVolume Spike Monitors - Newser
What makes Dianthus Therapeutics Inc. stock price move sharplyFree Deep Market Trend Analysis - Newser
How Dianthus Therapeutics Inc. stock performs during market volatilityFree Stock Selection - Newser
Why Dianthus Therapeutics Inc. stock attracts strong analyst attentionTriple Return With Stability - Newser
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 4.9%Should You Sell? - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 8.4%Should You Buy? - MarketBeat
DNTH’s Stock Market Adventure: -16.38% YTD Growth Amidst Volatility - investchronicle.com
What is William Blair's Estimate for DNTH FY2025 Earnings? - MarketBeat
William Blair Begins Coverage on Dianthus Therapeutics (NASDAQ:DNTH) - MarketBeat
FY2025 Earnings Estimate for DNTH Issued By William Blair - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Coverage Initiated at William Blair - Defense World
Dianthus Therapeutics stock rises after William Blair initiates coverage By Investing.com - Investing.com Canada
Dianthus Therapeutics Shares Climb After Analyst Coverage Boost - MSN
William Blair Initiates Dianthus Therapeutics at Outperform - MarketScreener
Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 6%Time to Sell? - MarketBeat
Is Dianthus Therapeutics, Inc. overvalued or undervalued? - MarketsMojo
Dianthus Therapeutics Inc Stock (DNTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.79%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):